Teknova Reports Fourth Quarter and Full Year 2025 Financial Results Teknova (Nasdaq: TKNO) reported full year 2025 revenue of $40.5M, up 7% year-over-year, and Q4 2025 revenue of $10.0M, up 8% year-over-year. The company provided 2026 revenue guidance of $42–44M and expects Free Cash Outflow of less than $10M for 2026.Gross margin improved to 33.2% for 2025; Adjusted EBITDA loss narrowed to -$6.7M. Cash and short-term investments were $21.3M with gross debt of $13.2M at year-end.

#TKNO Teknova Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/TKNO/teknova-report...

#TKNO Teknova Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/TKNO/teknova-report...

Teknova Reports Second Quarter 2025 Financial Results Teknova (Nasdaq: TKNO) reported strong Q2 2025 financial results with total revenue of $10.3 million, marking a 7% increase from Q2 2024. The company achieved four consecutive quarters of year-over-year growth and reaffirmed its 2025 revenue guidance of $39-42 million.Key financial metrics include: Lab Essentials revenue of $7.8 million (up 2%), Clinical Solutions revenue of $2.1 million (up 32%), and improved gross margin of 38.7% compared to 29.2% in Q2 2024. The company reported a net loss of $3.6 million ($0.07 per share), showing improvement from the $5.4 million loss in Q2 2024. Cash position stands at $24.0 million with total borrowings of $13.2 million.

#TKNO Teknova Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/TKNO/teknova-report...

Teknova Reports First Quarter 2025 Financial Results Teknova (NASDAQ: TKNO) reported its Q1 2025 financial results, showing total revenue of $9.8 million, a 5% increase from Q1 2024. The company's Lab Essentials segment grew 12% to $8.1 million, while Clinical Solutions revenue decreased 32% to $1.2 million. Gross margin improved to 30.7% from 23.8% year-over-year. The company reported a net loss of $4.6 million ($0.09 per share), compared to $8.1 million loss in Q1 2024. Notably, Teknova entered into a collaboration with Pluristyx to become the exclusive manufacturer and distributor of the PluriFreeze™ cryopreservation system in the US and Canada. The company maintained its 2025 revenue guidance of $39-42 million and expects free cash outflow of less than $12 million.

#TKNO Teknova Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/TKNO/teknova-report...

BREAKING NEWS: ( NASDAQ: #TKNO ) Trend Tracker for (TKNO)

Revolutionary Cell Therapy Preservation: Teknova's New PluriFreeze System Transforms Development Process Synthetic, animal-origin-free PluriFreeze system revolutionizes cell therapy preservation. Exclusive partnership brings advanced cryopreservation technology to US and Canada markets.

#TKNO Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

www.stocktitan.net/news/TKNO/teknova-and-pl...

Major Biotech Deal: Teknova Lands Exclusive Manufacturing Rights for Revolutionary Cell Therapy Preservation System Teknova gains exclusive manufacturing rights for PluriFreeze™, a breakthrough synthetic cryopreservation system, expanding its footprint in the growing cell therapy market.

#TKNO Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

www.stocktitan.net/news/TKNO/teknova-and-pl...

Teknova Reports Fourth Quarter and Full Year 2024 Financial Results Teknova (TKNO) reported its Q4 and full-year 2024 financial results, with total revenue reaching $37.7 million for FY2024, up 3% year-over-year. Q4 2024 revenue was $9.3 million, an 18% increase from Q4 2023.Key highlights include:Clinical Solutions revenue grew 110% in Q4 2024 to $1.9 million41% annual growth in Clinical Solutions customersLab Essentials revenue reached $6.8 million in Q4, up 2%Year-end cash position of $30.4 million with $12.1 million in gross debtThe company improved its operational efficiency and reduced cash burn, with free cash outflow decreasing to $13.5 million in 2024 from $26.7 million in 2023. For 2025, Teknova provided revenue guidance of $39-42 million with expected free cash outflow below $12 million.

#TKNO Teknova Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/TKNO/teknova-report...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish crossover of Moving Average Convergence Divergence signal, Tue Feb 11th - #VRNA #TKNO #RAIL #PBPB #VTEX #TNK #SES #ONTF #NAT #MG #GSBD #FPH #EHAB #DNA #OBIO #LMB #KRKR #INMB #GAME - More: crystalequityresearch.com/SmCpStr/ - #smallcap

JUST IN: ( NASDAQ: #TKNO ) How the (TKNO) price action is used to our Advantage

#StockMarket #News

Just In: ( NASDAQ: #TKNO ) (TKNO) Trading Advice

#StockMarket #News

Just In: ( NASDAQ: #TKNO ) Teknova Announces $15.4 Million Private Placement

#StockMarket #News